| **Characteristic** | **N = 2,055***1* |
| --- | --- |
| Gender |  |
| F | 1,042 (51%) |
| M | 1,013 (49%) |
| Age (years) at start of observation | 31 (26) |
| Age (years) at montelukast initiation | 36 (27) |
| Type of first asthma diagnosis |  |
| Emergency admission | 489 (24%) |
| Inpatient diagnoses | 1,097 (53%) |
| Outpatient visits | 469 (23%) |
| Number of hospitalization at montelukast initiation |  |
| 0 | 419 (20%) |
| 1 | 786 (38%) |
| 2 | 369 (18%) |
| More than 3 | 481 (23%) |
| Chronic obstructive pulmonary disease | 136 (6.6%) |
| Allergic Rhinitis | 130 (6.3%) |
| Sinusitis | 12 (0.6%) |
| Obesity | 27 (1.3%) |
| Gastroesophageal Reflux Disease (GERD) | 41 (2.0%) |
| Eczema | 113 (5.5%) |
| Diabetes Mellitus | 87 (4.2%) |
| Ischemic Heart Disease | 78 (3.8%) |
| Arrhythmia | 73 (3.6%) |
| Heart Failure | 70 (3.4%) |
| Hypertension | 213 (10%) |
| Osteoporosis | 97 (4.7%) |
| Short-acting beta agonists (SABA) | 1,795 (87%) |
| Methylxanthines | 186 (9.1%) |
| Inhaled corticosteroids (ICS) and/or long-acting beta agonists (LABA) | 1,763 (86%) |
| Short acting muscarinic antagonists (SAMA) | 456 (22%) |
| *1*n (%); Mean (SD) | |